Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented different innovative pricing and reimbursement models. In an article for MedTech Strategist, we explore whether similar innovative reimbursement and contracting schemes might be developed for medical technologies and how the challenges they bring might be overcome.
Assessing physician practices and expectations in the post-COVID era
The ongoing COVID-19 pandemic has affected the routines of many practicing physicians, including an impact on their prescribing decisions. For many physician...